Autoimmune Diseases  >>  Linjeta (prandial insulin)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Linjeta (prandial insulin) / Ipsen
NCT00542724 / 2006-006599-39: An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

Completed
3
462
US, Europe, RoW
VIAject™, Regular Human Insulin
Biodel
Type 1 Diabetes Mellitus
07/08
 

Download Options